GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.33 CNY | +1.51% |
|
+7.86% | +20.02% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,072 | 20,936 | 12,806 | 13,545 | 12,162 | 12,162 | - |
| Enterprise Value (EV) 1 | 24,072 | 19,373 | 12,005 | 12,730 | 9,309 | 11,233 | 11,299 |
| P/E ratio | 46.8 x | 45 x | 51.4 x | 78.5 x | 38.9 x | 32.4 x | 26 x |
| Yield | 0.65% | 0.67% | 0.6% | 0.74% | 2.06% | 0.91% | 1.66% |
| Capitalization / Revenue | 13.4 x | 12 x | 7.17 x | 7.82 x | 4.55 x | 4.21 x | 3.51 x |
| EV / Revenue | 13.4 x | 11.1 x | 6.72 x | 7.35 x | 4.18 x | 3.89 x | 3.26 x |
| EV / EBITDA | 37.8 x | 32.6 x | 38.4 x | 54.2 x | 27.6 x | 23.6 x | 18.8 x |
| EV / FCF | - | -50.1 x | -96.3 x | -204 x | 111 x | 49.8 x | 30.1 x |
| FCF Yield | - | -2% | -1.04% | -0.49% | 0.9% | 2.01% | 3.32% |
| Price to Book | 9.02 x | 7.03 x | 4.15 x | 4.25 x | 3.03 x | 3.38 x | 3.18 x |
| Nbr of stocks (in thousands) | 401,000 | 401,000 | 401,820 | 401,445 | 401,000 | 401,000 | - |
| Reference price 2 | 60.03 | 52.21 | 31.87 | 33.74 | 30.33 | 30.33 | 30.33 |
| Announcement Date | 21/04/20 | 23/04/21 | 29/04/22 | 28/04/23 | 26/04/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,801 | 1,745 | 1,787 | 1,732 | 2,226 | 2,887 | 3,466 |
| EBITDA 1 | 637.6 | 593.9 | 312.2 | 234.7 | 337.3 | 476.8 | 601.6 |
| EBIT 1 | 612.6 | 572.5 | 299 | 207.3 | 319.3 | 462 | 563.2 |
| Operating Margin | 34.02% | 32.81% | 16.73% | 11.97% | 14.35% | 16% | 16.25% |
| Earnings before Tax (EBT) 1 | 614 | 567.4 | 309.6 | 206.6 | 317.1 | 452.9 | 562.7 |
| Net income 1 | 514.9 | 464.4 | 247.9 | 174.2 | 259.4 | 373.7 | 464.4 |
| Net margin | 28.59% | 26.61% | 13.87% | 10.06% | 11.66% | 12.94% | 13.4% |
| EPS 2 | 1.284 | 1.160 | 0.6200 | 0.4300 | 0.6500 | 0.9369 | 1.165 |
| Free Cash Flow 1 | - | -386.6 | -124.6 | -62.45 | 83.98 | 225.4 | 375.6 |
| FCF margin | - | -22.15% | -6.97% | -3.61% | 3.77% | 7.81% | 10.84% |
| FCF Conversion (EBITDA) | - | - | - | - | 24.9% | 47.26% | 62.43% |
| FCF Conversion (Net income) | - | - | - | - | 32.37% | 60.31% | 80.89% |
| Dividend per Share 2 | 0.3900 | 0.3500 | 0.1900 | 0.2500 | 0.5200 | 0.2752 | 0.5039 |
| Announcement Date | 21/04/20 | 23/04/21 | 29/04/22 | 28/04/23 | 26/04/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 649.3 | - | 434.5 | 817.2 | 326.5 | 588 | - | - | 477 | 689.2 | 753.4 | 616.8 | 846.2 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 140.1 | - | 58.48 | 137.7 | 10.14 | 59.46 | - | - | - | 128.2 | - | - | - | - | - |
| Operating Margin | 21.57% | - | 13.46% | 16.85% | 3.11% | 10.11% | - | - | - | 18.6% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | 140.4 | - | 58.38 | - | 9.62 | 59.33 | - | - | 27.61 | 126.3 | 114 | 93.32 | 98.4 | - | - |
| Net income 1 | 105.9 | - | 51.59 | - | 2.941 | 54.17 | - | 130.7 | 43.14 | 85.59 | 93.26 | 76.35 | 75.98 | - | - |
| Net margin | 16.31% | - | 11.87% | - | 0.9% | 9.21% | - | - | 9.04% | 12.42% | 12.38% | 12.38% | 8.98% | - | - |
| EPS 2 | 0.2700 | - | 0.1300 | - | 0.0100 | 0.1300 | - | 0.3300 | 0.1000 | 0.2200 | 0.2326 | 0.1904 | 0.1895 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | 0.2707 | - | - | - | 0.3182 |
| Announcement Date | 29/04/22 | 26/05/22 | 26/08/22 | 26/08/22 | 28/10/22 | 28/04/23 | 25/05/23 | 25/08/23 | 30/10/23 | 26/04/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,563 | 801 | 814 | 824 | 930 | 864 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -387 | -125 | -62.5 | 84 | 225 | 376 |
| ROE (net income / shareholders' equity) | 26.3% | 16.5% | 8.15% | 5.56% | 7.94% | 10.5% | 12.5% |
| ROA (Net income/ Total Assets) | 18.5% | 12.8% | 6.56% | 4.44% | 6.42% | 8.61% | 8.95% |
| Assets 1 | 2,777 | 3,616 | 3,778 | 3,926 | 4,452 | 4,338 | 5,191 |
| Book Value Per Share 2 | 6.660 | 7.430 | 7.680 | 7.940 | 8.350 | 8.970 | 9.530 |
| Cash Flow per Share 2 | 1.160 | 0.9000 | -0.0200 | 0.1200 | 0.8400 | 1.120 | 1.390 |
| Capex 1 | 6.4 | 749 | 117 | 111 | 254 | 228 | 166 |
| Capex / Sales | 0.36% | 42.92% | 6.55% | 6.4% | 11.41% | 7.9% | 4.79% |
| Announcement Date | 21/04/20 | 23/04/21 | 29/04/22 | 28/04/23 | 26/04/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
30.33
CNY
Average target price
31.61
CNY
Spread / Average Target
+4.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.02% | 1.68B | |
| -3.10% | 251B | |
| +12.81% | 19.44B | |
| 0.00% | 17.73B | |
| +0.38% | 11.04B | |
| -6.60% | 10.11B | |
| +16.90% | 7.51B | |
| +10.15% | 5.97B | |
| -0.65% | 4.42B | |
| -18.81% | 3.7B |
- Stock Market
- Equities
- 603983 Stock
- Financials Guangdong Marubi Biotechnology Co., Ltd.
